PAREXEL, a multinational, life sciences consulting firm and contract research organization, announced a new collaboration with Eli Lilly, a global pharmaceutical company, to launch a clinical research learning and development program in China.
The program will bring high-value training opportunities to clinical trial sites in China and investigators, enhancing the execution of local clinical trials and driving innovation in biopharmaceutical industry.
PAREXEL and Lilly’s collaboration is based on a shared vision to address this unmet need and promote globalization and innovation of the drug development. The joint program will use curriculum developed by PAREXEL Academy for clinical trial investigators, and issue certifications to professionals who complete the training. Designed by clinical research practitioners, the curriculum combines the latest policies, regulations and clinical research technologies. It also uses behavior-oriented curriculum design, real-world cases, as well as advanced knowledge and industry trends, to provide world-class expertise and practical experience for clinical research investigators.
PAREXEL Academy develops education and training programs in the field of clinical research across Asia, Europe and the USA to meet the increasing demand for professionals and executives in the biopharmaceutical industry.